Two decades of GSK rotavirus vaccine (RV1): a global analysis to estimate vaccination completion and deaths averted in children under 5 years.
Saved in:
| Title: | Two decades of GSK rotavirus vaccine (RV1): a global analysis to estimate vaccination completion and deaths averted in children under 5 years. |
|---|---|
| Authors: | Genovez V; Health Economics & Market Access, Amaris Consulting, Lisbon, Portugal.; GlaxoSmithKline Biologicals SA, Wavre, Belgium., Berton O; GlaxoSmithKline Biologicals SA, Wavre, Belgium., Barthès S; GlaxoSmithKline Biologicals SA, Wavre, Belgium., Verelst F; GlaxoSmithKline Biologicals SA, Wavre, Belgium., Biundo E; GlaxoSmithKline Biologicals SA, Wavre, Belgium. |
| Source: | Expert review of vaccines [Expert Rev Vaccines] 2025 Dec; Vol. 24 (1), pp. 936-943. Date of Electronic Publication: 2025 Sep 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101155475 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8395 (Electronic) Linking ISSN: 14760584 NLM ISO Abbreviation: Expert Rev Vaccines Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
